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SialidosisThe lysosomal storage disease sialidosis is caused by a primary deﬁciency of the sialidase N-acetyl-α-
neuraminidase-1 (NEU1). Patients with type I sialidosis develop an attenuated, non-neuropathic form of
the disease also named cherry red spot myoclonus syndrome, with symptoms arising during juvenile/ adult
age. NEU1 requires binding to its chaperone, protective protein/cathepsin A (PPCA), for lysosomal compartmen-
talization, stability and catalytic activation.We have generated a newmousemodel of type I sialidosis that ubiq-
uitously expresses a NEU1 variant carrying a V54M amino acid substitution identiﬁed in an adult patient with
type I sialidosis. Mutant mice developed signs of lysosomal disease after 1 year of age, predominantly in the kid-
ney, albeit low residual NEU1 activity was detected in most organs and cell types. We demonstrate that the ac-
tivity of the mutant enzyme could be effectively increased in all systemic tissues by chaperone-mediated gene
therapy with a liver-tropic recombinant AAV2/8 vector expressing PPCA. This resulted in clear amelioration of
the disease phenotype. These results suggest that at least some of the NEU1 mutations associated with type I
sialidosis may respond to PPCA-chaperone-mediated gene therapy.
Published by Elsevier B.V.1. Introduction
N-acetyl-α-neuraminidase-1 (NEU1) initiates the degradation of
sialoglycoconjugates in lysosomes. NEU1 binds its chaperone, protec-
tive protein/cathepsin A (PPCA) to route to the lysosome and achieve
intralysosomal catalytic activity/stability [1–3]. In the lysosome,
NEU1 is active exclusively in a multienzyme complex with PPCA
and β-galactosidase. Two lysosomal storage diseases (LSDs) are asso-
ciated with NEU1 deﬁciency: sialidosis, which results from structural
mutations at the NEU1 locus on chromosome 6p21 [4–6], and
galactosialidosis (GS), which is caused by a primary defect of PPCA
leading to a secondary deﬁciency of NEU1 [7–9]. Because both dis-
eases involve severe NEU1 deﬁciency, their clinical onset and pro-
gression are overlapping. However, certain distinct systemic and
neurologic differences exist between the two diseases that likely re-
sult from the (near) complete PPCA and partial β-galactosidase deﬁcit
in GS patients [10,11].id; ERT, enzyme replacement
phoresis; GS, galactosialidosis;
out–transgenic; LSD, lysosomal
CA, protective protein/cathepsin
, wild-type
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.V.The numerous clinical manifestations of sialidosis vary in terms of
the age of onset and severity of the symptoms, mostly correlating
with the levels of residual NEU1 activity [5,12,13]. Patients with
type I sialidosis have the attenuated form of the disease, and mostly
develop symptoms during adolescence, which include myoclonus,
progressive visual loss, and bilateral cherry red spots. All patients di-
agnosed with this form of the disease have normal intellectual capac-
ity. The extent of disease severity in type I sialidosis largely correlates
with the type of NEU1 mutations and the residual NEU1 activity they
confer [5]. Some NEU1 variants segregating with type I patients
(R294S, 400dupHY, G328S, V54M) showed an increase in their cata-
lytic activity in response to an increase in the levels of PPCA [5]. Con-
genital type II sialidosis, on the other hand, is a fulminant disease.
Patients are stillborn or diagnosed at birth and have severe somatic
features, skeletal dysplasia, hepatosplenomegaly, and mental retarda-
tion. Infantile or juvenile type II sialidosis patients are relatively healthy
at birth, but also develop progressive visceromegaly, dysostosis multi-
plex, and moderate to severe mental retardation. Also for type II
sialidosis there is a clear correlation between the type of NEU1 muta-
tions and the severity of the disease [5].
A disease-threshold model explains the correlation between the
residual activity in patients with mild phenotypes [14]. This model
predicts that lysosomal hydrolase activity is normally higher than
needed for substrate turnover and tissue/organ homeostasis. Howev-
er, if the enzyme activity falls below the disease threshold, as it is the
case in LSD patients, its catalytic activity is not sufﬁcient to metabo-
lize substrates, resulting in disease onset and progression. For many
LSDs, the disease threshold may be as low as 1% to 5% of normal
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level of residual enzyme may explain variability in age of onset, dis-
ease severity, and symptoms in patients with sialidosis.
Neu1−/− mice develop a systemic disease that closely mimics the
early-onset type II form of sialidosis [16]. In particular, splenomegaly,
which is a recurrent feature in patients, coincides with the occurrence
of extramedullary hematopoiesis [17]. Previously, we have shown
that in Neu1−/− mice this and other phenotypes result at least in
part from exacerbation of the process of lysosomal exocytosis,
which is downstream of the Neu1 deﬁciency in various cell types, in-
cluding bone marrow (BM)-derived macrophages and connective tis-
sue ﬁbroblasts [17–19]. In addition, in the ﬁbroblasts of patients with
sialidosis we demonstrated an inverse correlation between residual
NEU1 activity and the level of lysosomal exocytosis, which may link
the exacerbation of this process to multiple disease manifestations
[17].
Enzyme replacement therapy (ERT) with recombinant lysosomal
hydrolases is an effective treatment for several non-neuropathic pa-
tients with LSDs [20]. Unfortunately, due to the unfavorable proper-
ties of NEU1 (i.e., it is prone to aggregate, unstable in the absence of
PPCA, lack mannose-phosphate recognition marker) no therapy is
currently available or foreseeable for patients with sialidosis. Besides
ERT, small-molecule, pharmacologic-chaperone therapy (PCT) may
be beneﬁcial for LSD patients with non-neuropathic attenuated
forms of LSDs [21–23]. PCT is based on the use of speciﬁc iminosugars
that can bind the active site of a mutant enzyme, thereby promoting
better folding, increased lysosomal trafﬁcking and catalytic activity/
stability. However, because single therapies are not universally effec-
tive, PCT may be more successful in combination with other treat-
ments [24].
Analogously to PCT, we hypothesized that increasing the concen-
tration of NEU1's physiological chaperone, PPCA, could facilitate the
lysosomal compartmentalization and stability of mutant forms of
NEU1 associated with type I and juvenile, type II sialidosis. To test
this hypothesis, we generated a new mouse model of the attenuated,
type I form of sialidosis, carrying a V54M-NEU1 amino acid substitu-
tion previously identiﬁed in a non-neuropathic adult patient [5]. We
treated type I sialidosis mice with a good manufacturing practice
(GMP)-grade self-complementary adeno-associated virus (scAAV)
expressing PPCA under the control of a liver-speciﬁc promoter [25].
This vector, expressing human factor IX, has been approved and suc-
cessfully used in a combined phase 1 and 2 gene-transfer clinical trial
in patients with Hemophilia B [26]. Recently we have successfully
used the same scAAV2/8 vector expressing PPCA in a preclinical
study in GS mice [25], a milestone in the development of a gene ther-
apy clinical trial for GS patients. Here, we present evidence that also
some patients with type I sialidosis may beneﬁt from gene therapy
treatment with the same PPCA-expressing scAAV2/8 vector.2. Material and methods
2.1. Cell culture and antibodies
Primary lung ﬁbroblasts were isolated from Neu1−/− (KO) mice
and maintained in culture in Dulbecco's modiﬁed Eagle's medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and anti-
biotics (100 units/mL penicillin, 100 μg/mL streptomycin). The cells
were maintained at 37 °C (5% CO2). The method for isolating primary
macrophages from fresh bone marrow (BM) of KO mice has been de-
scribed [27]. HEK293T and ecotropic (Phoenix-E) viral-producer cells
were grown in DMEM supplemented with 5% FBS. Antibodies against
NEU1 and PPCAwere produced and afﬁnity puriﬁed, as described pre-
viously [28]. A monoclonal antibody against the luminal domain of
Lamp1 (clone 1D4B) was obtained from Santa Cruz Biotechnology
(Santa Cruz, CA).2.2. Retrovirus preparation, transduction, and transient transfection
The MSCV-PPCA-IRES-GFP and MSCV-NEU1-IRES-GFP retroviral con-
structs have been used previously [29]. The V54M-NEU1 and Y370C-
NEU1 missense mutations have previously been previously described
and transiently expressed in ﬁbroblasts from patients with sialidosis [5].
The mutant NEU1 cDNAs were cloned into the retroviral vector
MSCV-IRES-GFP using standard cloning procedures. Ecotropic retrovi-
ruses were generated by transfecting retroviral packaging cell line
Phoenix-E with MSCV-NEU1WT-IRES-GFP, MSCV-NEU1V54M-IRES-GFP,
or MSCV-NEU1Y370C-IRES-GFP. Mouse KO ﬁbroblasts were either single-
transduced with the WT or 1 of 2 mutant MSCV-NEU1-GFP viral con-
structs, or they were cotransduced with the NEU1-expressing viruses
and MSCV-PPCA-IRES-GFP. BM-derived KO macrophages were trans-
ducedwith either theWTor 1 of the 2mutantMSCV-NEU1-GFPviral con-
structs. A ﬁnal concentration of 8 μg/mL polybrene was used to improve
transduction efﬁciency. Two or 3 days after transduction, GFP+ cells
were sorted by ﬂuorescence-activated cell sorting. Sorted cells were
maintained in culture for an extended period of time.
2.3. Animal studies
All experiments were performed on Neu1−/− (KO), Neu1−/−;
NEU1V54M (KO/TG), Neu1+/+;NEU1V54M (WT/TG), Ppca−/− mice in
the FVB background [16,17,30]. All experiments and handling proce-
dures described herein were approved by the St. Jude Children's Re-
search Hospital Animal Care and Use Committee.
2.4. Generation of Neu1−/−;NEU1V54M mice
The 1.2-kb human ubiquitin promoter fragment [31] was released
from the plasmid pFUGW by the restriction endonucleases PacI and
BamHI (New England BioLabs, Ipswich, MA) and treated with Klenow
(New England BioLabs) to generate blunt ends. Subsequently, the
ubiquitin promoter fragment was cloned upstream of the NEU1 cDNA
into the BamHI-linearized and Klenow-blunted pSCTOP-NEU1V54M plas-
mid DNA vector [5]. A 4.2-kb linear NEU1V54M transgene-containing
DNA fragment was released by digesting the plasmid DNA with ClaI
and SﬁI (New England BioLabs). The DNA fragment was injected into
the pronuclei of fertilized eggs isolated from FVB/NJ pregnant mice
[32]. Transgenic founders were PCR-genotyped using genomic DNA
extracted from the tails and 2 human NEU1 cDNA-speciﬁc oligonucleo-
tide primers (sense, 5′-gggcttaagggtgacatctgcgct-3′; antisense, 5′-agcag
ttgctccatggtcaccagc-3′) that generate a 288-bp fragment in transgene-
positive mice. NEU1V54M transgenic FVB mice were bred into the KO
FVB background [16] to generate mouse strains that are Neu1 mRNA-
negative, but instead express human mutant NEU1 under the control
of the ubiquitin promoter: knockout transgenic (KO/TG) Neu1−/−;
NEU1V54M mice.
2.5. Uptake assay of mouse ﬁbroblasts and macrophages in vitro
MSCV-transduced ﬁbroblasts and primary macrophages were seed-
ed in 6-well plates to near conﬂuency. Aliquots of puriﬁed BV-PPCA[28]
(3, 6, or 9 μg) were added to the culture medium of macrophages and
incubated for 48 h, after which the cells were trypsinized, washed in
PBS, centrifuged at 500 ×g, and frozen at−80 °C.
2.6. Production and titration of the scAAV2/8-LP1-PPCA vector
The production and titration of the scAAV2/8LP1-PPCA construct
have been described previously [25]. In brief, the vector contains a
liver-speciﬁc regulatory element that consists of the core domains
from the human apolipoprotein hepatic control region and the
human alpha-1-antitrypsin gene promoter [33] which drives the
hepatocyte-exclusive expression of the 1.44-kb human PPCA cDNA
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comparable transient-transfection procedure in the Children's GMP,
LLC facility on the St. Jude campus, as previously described for the he-
mophilia B vector [34].
2.7. Experimental design, injection of AAV, and collection of tissues and
urine
A single dose of 2.6 × 1011 vector genomes of scAAV2/8LP1-PPCA
was injected into the tail veins of four 16-month-old female KO/TG
mice. This dose was identical to the highest and optimal rAAV-dose
used previously in GS mice [25]. Four female WT/TG mice were not
injected and 4 female KO/TG mice were mock-injected with a sterile
saline solution. The mice were monitored for 4 weeks post injection,
after which they were euthanized. Urine was collected prior to treat-
ment and again just before euthanasia. Eleven tissues (BM, liver, kid-
ney, spleen, lung, skeletal muscle, heart, salivary gland, brain, and
ovary) were collected at the time of euthanasia. Tissues were ﬁxed
in 10% neutralized formalin and parafﬁn-embedded for histologic
and IHC analyses or frozen in liquid nitrogen for biochemical
analyses.
2.8. Cathepsin A and NEU1 activity assays, Western blot analysis, and si-
alic acid detection assay
NEU1 and cathepsin A enzyme assays and Western blot analysis
were performed on lysates of ﬁbroblasts and macrophages maintained
in culture. Brieﬂy, 2 pieces of frozen tissue of all rAAV-treated KO/TG
mice, as well as that of untreatedWT and KO/TG controls, were homog-
enized on ice in 3 volumes of water (w/v) using an Omni-Prep
Multi-Sample Homogenizer and soft-tissue disposable grinders (Omni
International, Kennesaw, GA). Frozen cell pellets were lysed by hypo-
tonic shock in ice-cold water. NEU1 catalytic activity was measured
against synthetic 4-methylumbelliferyl-α-D-N-acetylneuraminic acid
(Sigma-Aldrich, St. Louis, MO) [35], and cathepsin A activity was mea-
sured against the dipeptide Z-Phe-Ala [8]. Tissue homogenate and cell
lysate samples (5–30 μg) were resolved on 4% to 12% gradient poly-
acrylamide gels under denaturing and reducing conditions, transferred
onto Hybond-PVDFmembranes (Amersham, Piscataway, NJ), and incu-
bated with afﬁnity-puriﬁed anti-PPCA and peroxidase-conjugated
goat–anti-rabbit secondary antibodies (Jackson ImmunoResearch,
West Grove, PA). The enzyme was visualized using Super Signal West
Femto Chemiluminescence reagent (Thermo Scientiﬁc, Rockford, IL)
and the Chemi-Doc imaging system (Bio-Rad, Hercules, CA).
Aliquots of bone marrow extracellular ﬂuid (BMEF; 30 μL) isolated
from femurs and tibias of KO/TG mice, as described previously [36],
were analyzed on Western blots using the Lamp1-speciﬁc antibody.
The total sialic acid content in mouse kidney homogenates was mea-
sured using the Enzychrom Sialic Acid Assay Kit, according to the
manufacturer's instructions (BioAssay Systems, Hayward, CA).
2.9. Immunohistochemical analysis of mouse tissue sections
Parafﬁn-embedded tissue sections (6-μm thick) were subjected to
deparafﬁnization and antigen retrieval using standard histology
methods. After blocking with 0.1% bovine serum albumin and 0.5%
Tween 20, the sections were incubated overnight at room temperature
with anti-PPCA antibody [37]. The sections were washed and incubated
with biotinylated secondary goat anti-rabbit antibody (Jackson
ImmunoResearch Laboratory) for 1 h. Endogenous peroxidase was re-
moved by incubating the sections with 0.1% hydrogen peroxide for
30 min. Antibody detection was performed using the ABC Kit and
diaminobenzidine substrate (Vector Laboratories, Burlingame, CA),
and sections were counterstained with hematoxylin according to stan-
dard method. For histopathologic examination, parafﬁn-embeddedtissues from all 96 mice were cut into 6-μm thick sections and stained
using a standard H&E method.
2.10. Fluorophore assisted carbohydrate electrophoresis (FACE) analysis
Urine samples (10 μL) were tested for the presence of undegraded
HMWOs using the FACE urinary carbohydrate analysis kit, according
to the manufacturer's protocol (Glyko, Novato, CA).
3. Results
3.1. Low mutant V54M-NEU1 enzyme activity is restored by exogenous
PPCA
In previous in vitro studies we showed that mutant and wild-type
(WT) NEU1 activity could be substantially augmented by increasing
the concentration of its chaperone PPCA [3,5,29]. Based on these initial
observations, we decided to design a proof-of-principle in vivo study for
the potential use of PPCA, instead of NEU1, to treat non-neuropathic pa-
tients with the type I form of sialidosis. We have chosen the
V54M-NEU1 as representative mutation of type I sialidosis because
this NEU1 variant retains a residual activity that in the patient's ﬁbro-
blasts was shown to respond well to increased levels of PPCA, and this
mutation was identiﬁed in an adult patient with a mild form of the dis-
ease [5]. To further validate that missense V54M-NEU1 would respond
to increased PPCA levels, we transduced mouse Neu1−/− (KO) ﬁbro-
blasts with bicistronic MSCV-NEU1-GFP retroviral constructs express-
ing either WT-, V54M-, or Y370C-NEU1 with or without coexpression
of MSCV-PPCA-GFP. Y370C-NEU1, which was included as a negative
control, is a catalytically inactive mutant previously identiﬁed in a pa-
tient with congenital type II sialidosis [5].
Expression of NEU1 and PPCA in MSCV-transduced cells was ﬁrst
tested on Western blots that showed sustained expression levels of
both enzymes (Fig. 1a, lower panel). Coexpression of PPCA and
WT-NEU1 resulted in a 3-fold increase in NEU1 activity compared to
cells transduced with the WT-NEU1 vector alone (Fig. 1a). V54M-
NEU1-expressing ﬁbroblasts showed a similar, albeit overall smaller
increase in NEU1 activity in MSCV-PPCA-coexpressing cells (Fig. 1a).
In contrast, “catalytically dead” Y370C-NEU1-expressing ﬁbroblasts
showed no increase in NEU1 activity when coexpressed with PPCA
(Fig. 1a).
We next tested whether instead of de novo synthesized PPCA the
endocytic uptake of the enzyme would have a similar stimulatory effect
on theNEU1 activity.We have previously demonstrated in the GSmouse
model that macrophages internalized baculovirus (BV)-expressed PPCA
via the mannose-receptor, thereby efﬁciently restoring endogenous
NEU1 [28]. Therefore, we transduced KO macrophages with the same
WT and mutant MSCV-NEU1 vectors, and incubated these cells in the
presence or absence of insect cell-produced PPCA precursor (Fig. 1b,
lower panel). Analogously to the ﬁbroblast experiment, after uptake of
PPCA both WT-NEU1- and V54M-NEU1-expressing macrophages
showed a substantial increase in NEU1 activity, whereas Y370C-NEU1-
expressing cells did not (Fig. 1b).
3.2. Generation of an accurate mouse model of type I sialidosis
These initial results suggest that PPCA-mediated chaperone thera-
py could be beneﬁcial for some of the attenuated non-neuropathic
forms of sialidosis. To be able to test such therapy in vivo, we
engineered a mouse model expressing V54M-NEU1. In mammals
NEU1 is ubiquitously, albeit differentially, expressed in various organs
and cell types, with highest expression in the kidney [38]. We opted
to use the ubiquitin promoter to drive the expression of the V54M-
Neu1 transgene instead of the endogenous NEU1 promoter, because
it is unknown what size of the endogenous NEU1 promoter should
be used to ensure general and sustained expression of the transgene
Fig. 1. Rescue of NEU1 mutations by human PPCA. (a) Murine Neu1−/− ﬁbroblasts were transduced with MSCV-based retroviral vectors containing the cDNAs for V54M, Y370C, or
WT NEU1 and the GFP marker. GFP-expressing cells were sorted and transduced with an MSCV-PPCA-GFP (PPCA-GFP) retrovirus (+) or incubated with control medium (−). Cells
(n = 3) were assayed for NEU1 activity and analyzed on Western blots for NEU1, PPCA, and GAPDH levels. (b) Neu1−/− macrophages in culture were transduced with the same
MSCV-based NEU1 retroviral vectors and incubated with growth medium (−) or with growth medium containing recombinant BV-PPCA (+) for 48 h. Samples (n = 3) were an-
alyzed as in (a). Error bars indicate standard deviation.
Fig. 2.Measurement of cathepsin A andNeu1 activities in tissues of KO/TGmice. (a) NEU1
and (b) cathepsin A activities assayed in various tissue homogenates fromKO/TG (n = 4)
or WT/TG (n = 4) mice. Error bars indicate standard deviation.
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literature that describe the regulatory elements driving NEU1 expres-
sion [39]. Instead, the ubiquitin promoter was previously shown to
generate robust transgene expression in all major tissues and organs
[31]. A NEU1V54M transgenic founder was crossed into the Neu1−/−
(KO) FVB background to generate a new sialidosis knockout trans-
genic (KO/TG) mouse strain, Neu1−/−;NEU1V54M. These mutant mice
were viable and fertile with a gross-normal appearance. They also
lacked any obvious neurologic involvement and lived a normal lifespan.
Early disease hallmarks of 2- to 6-week-old KO mice (i.e., edema and
enlarged kidneys, liver, and spleen) were absent in KO/TG mice as old
as 1 year. However, KO/TG mice that were euthanized between 1 and
2 years of age had developed edema and enlarged kidneys similar to
what was observed in young KO mice [16,17]. Therefore, the KO/TG
mice appear to be a suitable delayed-onset model for non-neuropathic
type I sialidosis.
3.3. NEU1 activity is reduced in KO/TG mice
We measured the NEU1 activity in tissue homogenates of adult
KO/TG mice and Neu1+/+;NEU1V54M wild-type transgenic (WT/TG)
controls (Fig. 2a). The residual NEU1 activity was reduced in all KO/TG
organs; however, the extent of reduction varied greatly (Fig. 2a). Low
enzyme activity was detected in the BM, liver, salivary glands, and kid-
ney of KO/TG mice (Fig. 2a). In the latter tissue, residual NEU1 activity
was only 1% compared to WT/TG control values (Fig. 2a). In the heart,
spleen, lung, and brain, the residual NEU1 activity varied between 30%
and 80% of WT/TG control values (Fig. 2a). The normal appearance
and absence of visceral organ and neurologic abnormalities in adult
KO/TGmice younger than 1 year of age indicated that the residual mu-
tant NEU1 activity was sufﬁcient to prevent the onset of the disease in
most organs. It is noteworthy that in the KO mice, the complete loss of
Neu1 resulted in substantially increased catalytic activity of its chaper-
one PPCA in virtually all tissues and cell types tested (not shown). In
contrast, cathepsin A activity was normal in the organs of KO/TG mice
(Fig. 2b), indicating that the partial loss of NEU1 causes biochemical
and phenotypical effects that are distinct from those caused by com-
plete loss of the enzyme.
3.4. Adult KO/TG mice show signs of late-onset non-neuropathic sialidosis
The complete deﬁciency of Neu1 in Neu1-null mice results in ex-
acerbated lysosomal exocytosis in the BM, evident by the aberrant ac-
cumulation of active serine proteases and glycosidases in the BMextracellular ﬂuid (BMEF), resulting in the loss of BM-progenitors,
and the occurrence of extramedullary hematopoiesis and splenomeg-
aly [17]. A marker of excessive lysosomal exocytosis in KO mice is the
presence of large quantities of Lamp1 in the particulate fraction of
BMEF (Fig. 3a, lane 1). In contrast, despite the dramatic reduction in
Neu1 activity in the BM (Fig. 2a) and the severely reduced amount
of Neu1 in BM-derived macrophages (Fig. 3b, lane 3), the BMEF-
particulate fraction of KO/TG mice as old as 27 months of age
contained low amounts of Lamp1, similar to that in WT/TG mice
(Fig. 3). This result indicates that KO/TG BM cells are not excessively
exocytic and explains the absence of enlarged spleens in these mice.
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strates is evidenced by the extensive lysosomal vacuolization in all vis-
ceral organs and the brain, resulting in gross morphologic tissue
abnormalities [16,17]. in contrast, hematoxylin and eosin (H&E) stain-
ing of KO/TG tissue sections showed normal morphology in all organs
in mice as old as 1 year (not shown). However, in older KO/TGmice ly-
sosomal vacuolization was prominent in the glomeruli and Bowman's
capsules of the kidney which was comparable to that seen in sections
from 3-month-old KO mice (Fig. 4). Vacuolization was not detected in
the brains of KO/TGmice (not shown), which correlated with relatively
high residual Neu1 activity (Fig. 2a; 65% ofWT) and the absence of overt
neurological signs [16].
AlthoughH&E staining enabled us to analyze tissuemorphology and
detect abnormal vacuolization typical of LSDs, it is not quantitative and
lacks the sensitivity to assess an attenuated disease phenotype. A more
sensitive diagnostic method is the detection of high-molecular weight
oligosaccharides (HMWOs) in the urine of patients and mouse models
of LSDs [25]. Therefore, we analyzed the urine of 5- to 25-month-old
KO/TG mice for the presence of HMWOs by using ﬂuorophore-assisted
carbohydrate electrophoresis (FACE). HMWOs were present in the
urine of KO/TG mice as young as 5 months of age but were most abun-
dant in urine of a 25-month-old mouse (Fig. 4b). However, the amount
of HMWOs in the latter mouse did not reach that observed in a
4-month-old KO mouse (Fig. 4b). Nevertheless, FACE analysis detected
the onset of oligosacchariduria in KO/TG mice at least 6 months before
it could be detected byH&E staining of tissue sections.We conclude that
KO/TG mice represent a faithful model of attenuated type I sialidosis,
suitable to test PPCA-mediated chaperone therapy.Fig. 4. Late onset of sialidosis in KO/TGmice. (a) H&E staining shows normal kidneymor-
phology in an 11-month-old KO/TG mouse but extensive vacuolization in the glomeruli
and Bowman's capsules in a 19-month-old KO/TG mouse, comparable to that seen in a
3-month-old KO mouse with sialidosis. (b) FACE analysis of urine from KO/TG (ko; +)
mice (5–25 months old) shows elevated levels of HMWOs, namely glucose-4 (G4). How-
ever, the level of HMWOs in urine from a 4-month-old KO (ko;−)mousewith sialidosis is
several-fold higher compared to that in a 25-month-old KO/TG mouse. This is consistent
with a mild sialidosis phenotype in KO/TG mice.3.5. Uptake of PPCA by KO/TG macrophages increases NEU1 activity to
WT levels
We previously showed that the secondary Neu1 defect in Ppca-null
mice was rescued upon restoration of PPCA expression [25]. To assess
whether KO/TG mice would be receptive to chaperone therapy with
PPCA, we ﬁrst performed in vitro uptake assays with BV-expressed
PPCA. BM-derived macrophages isolated from KO/TG, KO, Ppca−/−,
and WT mice were cultured in the presence or absence of increasing
amounts of BV-expressed PPCA precursor [28]. Cells were then analyzed
for increased cathepsin A and NEU1 activities (Fig. 5a and c). Efﬁcient
uptake of PPCA was conﬁrmed by Western blot analysis of macrophage
lysates using a PPCA polyclonal antibody (Fig. 5c). All 4 primary macro-
phage cultures showed a concentration-dependent increase in cathep-
sin A activity, which reached a 10 fold increase in KO/TG and KO
macrophages (Fig. 5a). Moreover, after uptake of exogenous PPCA
NEU1 activity in both Ppca−/− andKO/TGmacrophageswas comparable
to that in untreated WT macrophages (Fig. 5c).Fig. 3.Western blot analysis of BMEF and BM-derived macrophages. (a) The amount of
Lamp1 in BMEF (30 μg) of KO/TG (ko; +) mice (17–27 months old) is comparable to
that in 17–25 month-old WT/TG Neu1−/− (wt; +) mice. (b) Western blot analysis of
KO/TG macrophages using a Neu1-speciﬁc polyclonal antibody shows a dramatic de-
crease in the expression of Neu1 compared to WT (wt;−) cells. As expected, KO mac-
rophages are devoid of Neu1.3.6. ScAAV2/8LP1-PPCA-treated KO/TG mice express high levels of exoge-
nous PPCA
We then assessed whether NEU1 activity could be increased in
vivo by treating KO/TG mice with exogenous PPCA. Tissues in KO/TG
mice have sufﬁcient endogenous cathepsin A activity to allow for a
late onset disease phenotype. Based on our in vitro studies, we pre-
dicted that increasing the levels of PPCA in these mice could prevent
or ameliorate their disease symptoms. Pilot experiments with tail
vein injections of Chinese hamster ovary- or BV-expressed PPCA in
young adult KO/TG mice resulted in a moderate (10%–30%) increase
in cathepsin A activity in the visceral organs. However, this level of
activity did not increase the residual activity of the mutant NEU1 en-
zyme (not shown), suggesting that this type of approach would not
be an effective therapy.
In a recent preclinical gene therapy trial in Ppca−/−mice, we used
the liver-speciﬁc, scAAV2/8LP1 PPCA-expression vector to correct the
disease phenotype [25]. We showed that the liver-produced PPCA zy-
mogen was secreted and efﬁciently taken up by cells of most systemic
organs, restoring both cathepsin A and Neu1 activities. Therefore, we
decided to also treat a cohort of KO/TG mice older than 1 year of age
with a single dose tail vein injection (2.6 × 1011 vector genomes/
Fig. 5. Uptake of BV-PPCA by KO/TG BM-macrophages rescues mutant NEU1 activity.
KO/TG (n = 3), WT (n = 3), and Ppca-KO (n = 3) macrophages that were
maintained in culture for 2 days in the presence of increasing amounts of BV-PPCA
(3, 6, 9 μg) (a) show a PPCA-dose dependent increase in cathepsin A activity. (b) The
amount of PPCA detected on a Western blot correlates with cathepsin A activity in
the corresponding cells. (c) KO/TG macrophages maintained in culture in the presence
of BV-PPCA show a dramatic increase in mutant NEU1 activity that is comparable to
that in WT cells and in BV-PPCA-treated Ppca-KO macrophages. KO macrophages,
which were used as a negative control, show no increase in NEU1 activity because
they lack endogenous NEU1. Error bars indicate standard deviation.
Fig. 6. Immunohistochemical analysis of PPCA in systemic organs of scAAV2/
8LP1-PPCA-treated KO/TG mice. A human PPCA-speciﬁc antibody readily detects the en-
zyme (brown punctate staining) in various tissue sections of scAAV2/8LP1-PPCA-treated
mice.
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showed clear signs of kidney disease, making it possible to assess
whether a short-term gene therapy treatment reversed the pheno-
type. Treated mice were euthanized 1 month after AAV injection.
Immunohistochemical analysis (IHC) using a polyclonal antibody
speciﬁc for human PPCA showed widespread high levels of PPCA ex-
pression in various organs and tissues, including the liver, kidney,
spleen, heart, intestine, adipose tissue, and muscle (Fig. 6). However,
as anticipated, PPCA was not detected in the brain (not shown). In
agreement with the IHC results, cathepsin A activity in the tissue ly-
sates of the AAV-injected mice showed an 86-fold increase in the
liver, 9-fold in the BM, 4.4-fold in the spleen, 3.6-fold in the heart,
2.4-fold in the skeletal muscle, 1.9-fold in the kidney, and no increase
in the brain (Fig. 7a). Western blot analysis using a human PPCA-
speciﬁc antibody conﬁrmed the robust expression of exogenous
PPCA in the various tissue lysates (Fig. 7b).3.7. ScAAV2/8LP1-PPCA-treated KO/TG mice express increased levels of
mutant NEU1 activity
In concordance with the increase in cathepsin A activity in AAV-
PPCA-treated mice, the NEU1 activity was increased in all tested or-
gans, except the brain (Fig. 7c). The average increase in NEU1 activity
in tissues of rAAV-PPCA-treated mice was 1.9 fold. Unexpectedly,
tissues with the highest increase in cathepsin A activity (liver, BM,
and spleen) showed only a moderate 1.3- to 1.6-fold increase in
NEU1 activity, whereas tissues with a lower increase in cathepsin A
activity (kidney, muscle, heart) showed higher NEU1 activity levels
(Fig. 7c). We reasoned that, because the endogenous cathepsin A
activity in WT and untreated KO/TG mice was already very high
Fig. 7. Cathepsin A and NEU1 activities in scAAV2/8LP1-PPCA-treated KO/TG mice. Cathepsin A and NEU1 activities were measured in tissue homogenates of scAAV2/
8LP1-PPCA-treated KO/TG mice (n = 4) and untreated KO/TG (n = 4) control mice. The (a) cathepsin A and (c) NEU1 activities are higher in tissues from rAAV-treated KO/TG
mice than in the corresponding untreated KO/TG mice. Error bars indicate standard deviation. (b) Immunoblot analysis of PPCA in tissues homogenates of 2 scAAV2/
8LP1-PPCA-treated KO/TG (KO/TG + PPCA) mice and untreated KO/TG and WT/TG controls.
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concentration of the enzyme in these tissues was most likely already
near the saturation level. This could explain why the rAAV-PPCA-
mediated increase in the amount of PPCA above the saturation level
resulted only in a modest increase in NEU1 activity (Fig. 7b). In
contrast, in the muscle and heart of WT and untreated KO/TG mice,
the level of endogenous cathepsin A activity was relatively low
(≤15 nmol·min−1·mg−1) and thus less likely to be saturated (Fig. 2b).
3.8. ScAAV2/8LP1-PPCA-treated KO/TG mice have reduced vacuolization
in the kidney
Chaperone-mediated gene therapy with scAAV2/8LP1-PPCA in-
creased residual NEU1 activity in non-neurogenic tissues by about 2
fold; thus, we questioned whether this treatment would be sufﬁcient
to prevent or reverse vacuolization in the kidney. H&E staining of kid-
ney sections from treated KO/TG mice showed that the glomeruli and
Bowman's capsules had reduced vacuolization (Fig. 8a). However,
urine from scAAV2/8LP1-PPCA-treated KO/TGmice that was collected
post-treatment still contained elevated levels of HMWOs (Fig. 8b).
The total (free and bound) sialic acid content in kidney lysates from
KO/TG mice was only marginally reduced in scAAV2/8LP1-PPCA-
treated KO/TG samples (Fig. 8c). Despite the modest decrease in sialic
acid content in the most affected organ, the kidney, the morphology
of the tissue appeared considerably improved (Fig. 8a). Because the
treated KO/TG mice were old, we think that the overall effects of
scAAV-PPCA treatment on the mutant NEU1 activity and improved
kidney morphology are very encouraging.
4. Discussion
Here we describe the generation of a new mouse model of the
non-neuropathic attenuated type I form of sialidosis, carrying a V54Mamino acid substitution identiﬁed in a type I sialidosis patient [5]. We
used these type I sialidosis mice in an explorative scAAV-based PPCA-
mediated chaperone gene therapy study. We ﬁrst showed that in this
mousemodel, as it is the case for type I sialidosis patients, disease symp-
toms and progression occur later in life (>1 year of age) and that the
disease is mild and non-neuropathic [12]. Because of the known depen-
dence of NEU1 on its chaperone PPCA for efﬁcient lysosomal routing
and intralysosomal activity and stability [1], we hypothesized that rais-
ing the concentration of PPCA above endogenous levels, could poten-
tially increase the stability and residual activity of mutant forms of
NEU1. As a consequence, the mutant NEU1 activity could be raised
near or above the disease threshold level, thereby slowing or reversing
the lysosomal accumulation of undegraded substrates.
We recently used the scAAV2/8LP1-PPCA vector in a comprehen-
sive preclinical dose-escalation study in Ppca-null mice, a model of
GS [25]. In this study we showed that, although the expression of
the corrective enzyme was restricted to the liver in the treated
mice, the circulating zymogen was efﬁciently internalized by cells of
virtually all visceral organs, thereby restoring endogenous PPCA and
NEU1 activity. This resulted in complete reversal of visceral organ his-
topathology, clearance of HMWOs from urine, and restoration of fer-
tility. This AAV-based dose-escalation study in GS mice set the stage
for PPCA-mediated chaperone gene therapy in type I sialidosis mice
that, unlike Neu1-null mice, have residual mutant NEU1 activity in
all organs.
We ﬁrst proved that in vitro augmentation of PPCA expression in
murine type I sialidosis macrophages and ﬁbroblasts expressing
V54M-NEU1 raised the mutant NEU1 activity near WT levels. Next,
in choosing the deﬁcient mice to be treated with the AAV-PPCA vec-
tor, we considered potential age effects on the curative efﬁcacy. For
instance, the AAV-treatment of neonatal Fabry mice was shown to
be more effective than similar treatment of adult Fabry mice [40].
However, we also had to consider that the most likely candidates
Fig. 8. Kidney morphology in scAAV2/8LP1-PPCA-treated KO/TG mice. (a) H&E staining
shows vacuolization in the glomeruli and Bowman's capsules of an untreated KO/TG
mouse but little vacuolization in the kidneys of 2 rAAV-PPCA-treatedmice. (b) FACE analy-
sis of urine from 2 rAAV-PPCA-treated KO/TG (ko;+;+)mice shows comparable amounts
of HMWOs compared to that in untreated KO/TGmice (ko;+;−). (c)Measurement of the
total sialic acid content in the kidneys of rAAV-PPCA-treated KO/TG mice (n = 4) shows a
12% decrease in the level of sialic acid compared to that in untreated KO/TG mice (n = 4).
Although the decrease in sialic acid content was not statistically signiﬁcant, the experiment
was performed in triplicate and consistently showed a 10% to 12% decrease in sialic acid
content in the kidneys of rAAV-PPCA-treated KO/TG mice. Error bars indicate standard
deviation.
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juvenile and adult patients. Therefore, we chose to treat 16-month-
old symptomatic type I sialidosis mice with a single tail vein injection
of high-dose scAAV2/8LP1-PPCA vector and assessed the effects of
treatment 1 month later. Treated mice showed increased PPCA ex-
pression in all organs, except the brain, and consequently, an average
of about 2-fold higher residual NEU1 activity than untreated mice. Al-
though this was not enough to completely reverse the lysosomalstorage phenotype, it reduced vacuolization and improved tissue
morphology in the kidney.
Small synthetic iminosugars are active site-speciﬁc compounds
that help fold mutated lysosomal glycosidases and allow more en-
zyme to pass the endoplasmic reticulum-quality control systems
and be routed to the lysosomal compartment [21]. However, this
strategy will be effective only for mutations that do not involve cata-
lytic site residues. PPCA appears to play a similar physiological role for
NEU1, with the added beneﬁt of a 2-fold action: ﬁrst, PPCA binds to
NEU1 early after synthesis to form a heterodimeric complex and as
such is routed to the lysosomal compartment. Second, in the lysosom-
al compartment, complex formation between the 2 enzymes further
promotes catalytic activation and stability of NEU1 [1–3]. This ap-
proach would not be effective for mutations that involve the catalytic
site of NEU1, such as the Y370C mutation identiﬁed in a type II
sialidosis patient [5], or for those mutations responsible for both vis-
ceral organ as well as CNS-pathology in type II sialidosis patients.
However, the majority of the NEU1 missense mutations do not in-
volve the catalytic site; therefore, we propose that besides the
V54M mutation used in this proof of principle study, also other
sialidosis patients with different NEU1 missense mutations could po-
tentially beneﬁt from PPCA-mediated chaperone therapy [5,6]; ap-
proximately 50% of patients with sialidosis have the attenuated
non-neuropathic type I form of the disease, and they carry at least
one of the 11 NEU1 mutant alleles (400dupHY, E377X, V54M, L111P,
V217M, G219A, V275A, R294S, P316S, G328S, T345I) known to confer
this phenotype [6]. Because the available amount of PPCA appears to
be rate limiting for the level of NEU1 activity, it is unclear whether
synthetic pharmacologic chaperones could also be effective in in-
creasing mutant NEU1 levels. Our data indicate that it may be worth-
while to explore strategies aimed at enhancing PPCA expression
pharmacologically.
We have also considered using an AAV-based gene therapy ap-
proach to treat the type I sialidosis with a scAAV2/8LP1 vector express-
ing NEU1 instead of PPCA. However, we do not think this would be a
better option because, unlike PPCA, NEU1 is poorly mannose-6-
phosphorylated, which would result in poor internalization of the
liver-produced and secreted enzyme by cells in other systemic organs
[1]. In addition,we have previously shown that theNEU1 enzyme is im-
munogenic, which would raise concerns about the development of
adverse immunologic reactions in patients [41]. Therefore, the PPCA-
mediated chaperone gene therapy described here could be the best
therapeutic option for some patients with type I sialidosis, who could
be enrolled in an anticipated scAAV2/8LP-PPCA gene transfer trial
designed for non-neuropathic GS patients.
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